Condition: Cardiovascular Morbidity · Cardiovascular Risk Assesment · Primary Prevention CVD · Sponsor: National Institute of Cardiovascular Diseases, Pakistan
More research is needed to articulate the most effective ways to use these tools as screening tests in cardiovascular risk assessments and how they ultimately affect CVD mortality and morbidity outcomes. Clinicians are encouraged to continue sharing decision-making with patients to combine their unique cardiovascular risk factors and develop a comprehensive, effective treatment plan.
This description comes directly from the study's public registry record.
Dr Rubina Rauf · +923002947117 · drrubinarauf@gmail.com
Musa Karim · +923323646169 · mkarim.nicvd@gmail.com
Always discuss trial participation with your own doctor first.
| National Institute of Cardiovascular Diseases | Karachi, Sindh, Pakistan | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06503341